What We're Reading: Page 2
Industry reads hand-picked by our editors
May 18, 2022
-
The Wall Street Journal
Cerebral Board Members Agree to Replace CEO Amid Federal Probe Into Prescription Practices
-
Bloomberg
Where Are the Paxlovid Combination Trials?
-
Endpoints News
Chinese pharma giant Hengrui launches new company for globalization play — with a Merck KGaA vet at the helm
-
C&EN
New day for antibody-drug conjugates
May 17, 2022
-
The Wall Street Journal
Pfizer's Covid-19 Booster Cleared for 5- to 11-Year-Olds
-
The New York Times
Targeting the Uneven Burden of Kidney Disease on Black Americans
-
Reuters
AstraZeneca boosts COVID portfolio with RQ Bio deal
-
FiercePharma
GlaxoSmithKline is no more: Meet the scaled down 'GSK'
May 16, 2022
-
Bloomberg
Apollo to Buy Stake in European Life Sciences VC Firm Sofinnova
-
The Wall Street Journal
Moderna Says It Wasn’t Aware of Investigation Into Its New CFO
-
Nature Biotechnology
Reflections on Alnylam
-
The Atlantic
The U.S. Is About to Make a Big Gamble on Our Next COVID Winter
May 13, 2022
-
Kaiser Health News
It Was Already Hard to Find Evusheld, a Covid Prevention Therapy. Now It’s Even Harder.
-
FirstWord Pharma
CSL's Vifor buyout delayed as it awaits antitrust approvals
-
STAT
Caribou CAR-T therapy shows blood-cancer remissions in first data reveal
-
NPR
COVID vaccine has given new impetus to developing an HIV vaccine
May 12, 2022
May 11, 2022
-
The Wall Street Journal
This Biotech Flew High, Then Fell Hard When Its Cancer Drug Failed
-
The New York Times
Emergent Hid Evidence of Covid Vaccine Problems at Plant, Report Says
-
Reuters
J&J appoints consumer health head Thibaut Mongon to CEO of spun-off business
-
C&EN
A toxic twist on AI for drug design
May 10, 2022
-
Bloomberg
'Please Pay Attention': Scientist Flagged Heart-Pill Toxins Early On
-
Associated Press
Rare cases of COVID returning pose questions for Pfizer pill
-
The Wall Street Journal
Moderna Seeks to Dismiss Covid-19 Vaccine Patent Lawsuit
Previous
